MonashHeart and Monash Cardiovascular Research Centre, Monash Medical Centre, 246 Clayton Road, Melbourne, Vic 3168, Australia.
Heart Lung Circ. 2010 Jan;19(1):11-8. doi: 10.1016/j.hlc.2009.05.707. Epub 2009 Dec 22.
Drug-eluting stents (DES) offer an attractive option for the treatment of acute thrombotic lesions during acute ST-elevation myocardial infarction (STEMI) due to their ability to inhibit restenosis. Several randomised trials have demonstrated the efficacy of DES in reducing target vessel revascularisation (TVR) in this setting. However, several registries of real-world patients receiving DES for STEMI have raised long-term safety concerns about DES use in this patient subset. Given the inherent limitations of registry data, this issue is likely to remain unresolved until further data is made available from large-scale ongoing trials with long-term follow-up such as the HORIZONS-AMI trial.
药物洗脱支架 (DES) 因其能够抑制再狭窄，为急性 ST 段抬高型心肌梗死 (STEMI) 期间急性血栓性病变的治疗提供了一个有吸引力的选择。几项随机试验已经证明了 DES 在降低该情况下靶血管血运重建 (TVR) 方面的有效性。然而，几项真实世界患者接受 DES 治疗 STEMI 的登记研究对 DES 在这一患者亚组中的使用提出了长期安全性问题。鉴于登记数据的固有局限性，在 HORIZONS-AMI 试验等具有长期随访的大型正在进行的试验提供更多数据之前，这个问题可能仍未得到解决。
